Breaking News Instant updates and real-time market news.

ALXN

Alexion

$98.07

0.84 (0.86%)

, BIIB

Biogen

$304.83

4.09 (1.36%)

09:31
01/03/19
01/03
09:31
01/03/19
09:31

Piper sees Alexion, Biogen as potential targets after Celgene buyout

Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.

ALXN

Alexion

$98.07

0.84 (0.86%)

BIIB

Biogen

$304.83

4.09 (1.36%)

BMRN

BioMarin

$84.97

-0.17 (-0.20%)

AIMT

Aimmune

$24.36

0.47 (1.97%)

DCPH

Deciphera

$22.42

1.49 (7.12%)

RIGL

Rigel Pharmaceuticals

$2.35

0.05 (2.17%)

CELG

Celgene

$66.65

2.51 (3.91%)

BMY

Bristol-Myers

$52.02

0.46 (0.89%)

  • 03

    Jan

  • 03

    Jan

  • 03

    Jan

  • 06

    Jan

  • 07

    Jan

  • 24

    Jan

  • 28

    Jan

  • 29

    Jan

  • 18

    Feb

  • 18

    May

  • 20

    May

ALXN Alexion
$98.07

0.84 (0.86%)

12/24/18
STFL
12/24/18
NO CHANGE
STFL
Hold
Alexion consensus will need to come down due to Ultimoris pricing, says Stifel
Stifel analyst Paul Matteis said Alexion's U.S. pricing for Ultomiris is below what he had modeled and it does not appear to him that sell-side numbers align with the company's conservative pricing strategy, leading him to tell investors that "Street numbers will need to come down to incorporate a new reality." However, he also sees "two major positives" from the pricing decision: namely that it should provide a "huge" tailwind for Soliris-to-Ultomiris conversions and that the company should earn "valuable brand equity" with payors. Matteis keeps a Hold rating on Alexion shares.
12/21/18
PIPR
12/21/18
NO CHANGE
Target $177
PIPR
Overweight
Piper says Alexion early approval should help continue complement 'dominance'
Piper Jaffray analyst Christopher Raymond notes that expectations were for Ultomiris to be approved in February, meaning today's decision came roughly two months early, which will pull forward the timeline for Alexion's market conversion from Soliris to Ultomiris. The earlier than expected approval, along with the "high bar Ultomiris has set," positions Alexion to "continue its dominance in the complement space," said Raymond. He maintains an Overweight rating and $177 price target on Alexion shares.
12/21/18
RAJA
12/21/18
NO CHANGE
RAJA
Outperform
Alexion's early ultomiris approval 'arrives at perfect time,' says Raymond James
Raymond James analyst Laura Chico noted that FDA approval of Alexion's ultomiris comes nearly two full months before the PDUFA date, stating that the approval "arrives at a perfect time and facilitates a potentially earlier 2019 launch." The approval should help lift an overhang on shares, said Chico, who likes the setup for the stock for 2019 and keeps an Outperform rating on Alexion shares.
12/10/18
RBCM
12/10/18
NO CHANGE
RBCM
Outperform
RA Pharmaceuticals could be strategic target for Alexion, says RBC Capital
RBC Capital analyst Kennen MacKay believes RA Pharmaceuticals' (RARX) zilucoplan gMG data "should impress even the skeptics," but he has received questions about why the stock hasn't inflected higher on data that left him "overall highly impressed." He believes the recent run-up of the stock into the data suggests anticipation of a positive result and also thinks the upside has likely been limited by some anticipation for a dilutive financing. Commenting on why the news "isn't more negative" for Alexion (ALXN), MacKay added that he anticipates that Alexion could have strategic interest in an acquisition of RA, with sufficient financial flexibility to pursue a deal, as the latter gets closer to commercialization. MacKay maintains an Outperform rating on RA Pharmaceuticals shares.
BIIB Biogen
$304.83

4.09 (1.36%)

01/01/19
PIPR
01/01/19
NO CHANGE
Target $400
PIPR
Overweight
Biogen raised prices on MS drugs meaningfully today, says Piper Jaffray
According to Wolters Kluwer Health, Biogen took "meaningful" price increases across its multiple sclerosis franchise effective January 1, 2019, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Starts The New Year Off With Spate of Price Increases." The timing and magnitudes of the increases are consistent with Biogen's established pattern, adds the analyst. Raymond, however, finds the company's increases this year notable, "especially in an environment of increasing drug pricing scrutiny on both the political and policy front." Biogen took a price increase of 6% for Tecfidera, 3.5% for Tysabri and 2% each for Avonex and Plegridy, he explains. Given President Trump's Drug Pricing Blueprint and his willingness to call out individual companies for price increases, the analyst thinks some investors will be surprised by Biogen's 2019 increases. He remains a buyer of Biogen shares with an Overweight rating and $400 price target. The stock closed Monday up $7.40 to $300.92.
12/21/18
12/21/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Overweight at Piper Jaffray. 2. Biogen (BIIB) initiated with a Buy at BTIG. 3. Allena Pharmaceuticals (ALNA) assumed with a Buy at B. Riley FBR. 4. WWE (WWE) initiated with a Hold at Loop Capital. 5. Applied Materials (AMAT) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/21/18
BTIG
12/21/18
INITIATION
Target $362
BTIG
Buy
BTIG starts Biogen with Buy rating, $362 price target
BTIG analyst Thomas Shrader last night initiated coverage of Biogen with a Buy rating and $362 price target. The analyst sees the company as well positioned with a "history of investing in imaging approaches for R&D, a hard-nosed business culture, a focus on neuroscience, and a cash-cow stable" of multiple sclerosis drugs. Further, Shrader expects "excitement to build over the aducanumab" story as we near the first Phase 3 readouts.
12/20/18
BTIG
12/20/18
INITIATION
Target $362
BTIG
Buy
Biogen initiated with a Buy at BTIG
BTIG initiated Biogen with a Buy rating and a price target of $362.
BMRN BioMarin
$84.97

-0.17 (-0.20%)

01/02/19
01/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Henry Schein (HSIC) downgraded to Neutral from Outperform at Baird with analyst Jeff Johnson saying he is more cautious on the combination of the dental sector's secular overhangs, softer Q4 patient volume checks, and accelerating equipment pricing pressures. 2. Conagra Brands (CAG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jason English saying while the stock's 41% decline since October 23 is overdone, the "path of recovery is likely to be protracted." 3. BioMarin (BMRN) downgraded to Market Perform from Outperform at Raymond James with analyst Laura Chico saying BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. 4. Hologic (HOLX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lewis saying his checks with about 40 medspas highlighted market saturation of body sculpting devices. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the steep drop-off in 2H 2018 panel pricing and challenging 1H 2019 comparisons versus 1H 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
12/18/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Logitech (LOGI) initiated with an Outperform at Wedbush. 2. Alnylam (ALNY) initiated with a Buy at Guggenheim, while BioMarin (BMRN) was initiated with a Neutral. 3. Tailored Brands (TLRD) initiated with a Buy at B. Riley FBR. 4. Adecogro (AGRO) initiated with a Neutral at Citi. 5. Shopify (SHOP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/19
RAJA
01/02/19
DOWNGRADE
RAJA
Market Perform
BioMarin downgraded to Market Perform on lack of catalysts at Raymond James
As previously reported, Raymond James downgraded BioMarin to Market Perform from Outperform Analyst Laura Chico said BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. The analyst notes key valorx events do not manifest until mid-2019, and vosoritde later in the year.
01/02/19
RAJA
01/02/19
DOWNGRADE
RAJA
Market Perform
BioMarin downgraded to Market Perform from Outperform at Raymond James
AIMT Aimmune
$24.36

0.47 (1.97%)

12/21/18
PIPR
12/21/18
NO CHANGE
PIPR
Aimmune BLA submission right on time, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $60 price target on Aimmune Therapeutics following the AR101 BLA submission for peanut allergy in children and adolescents ages 4-17. The analyst said he expects "this BLA will not only be accepted but may also receive Priority Review, putting it on track for a late summer approval/launch" and believes "the FDA will like this one." Raymond continues to "view the set-up on this name as decidedly positive" and remains a buyer of Aimmune shares.
12/19/18
PIPR
12/19/18
NO CHANGE
PIPR
Overweight
Aimmune retains competitive edge over DBV Technologies, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond thinks the recent disclosure that DBV Technologies' (DBVT) Viaskin Peanut may be excluded from the PDUFA program would likely mean an extended FDA review time, which he said "bodes well" for competitor Aimmune (AIMT), which this morning announced the initiation of its Phase 3 POSEIDON trial assessing the efficacy of AR101 in peanut-allergic children. Given that he reads the trial start as a sign that the FDA remains comfortable with the safety profile of AR101, and his view on AR101's clinical profile, Raymond said he believes Aimmune "retains the competitive edge" over DBV. He keeps an Overweight rating on Aimmune shares.
12/13/18
CANT
12/13/18
NO CHANGE
Target $64
CANT
Overweight
Aimmune current range an attractive entry point, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan sees the current Aimmune Therapeutics trading range as an attractive entry point. He reiterates an Overweight rating on the shares with a $64 price target after attending the company's analyst day.
12/20/18
PIPR
12/20/18
NO CHANGE
Target $60
PIPR
Overweight
DBV application withdrawal 'clears the way' for Aimmune, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics (AIMT) with a $60 price target after competitor DBV Technologies (DBVT) voluntarily withdrew its FDA application for Viaskin Peanut based on deficiencies in the manufacturing portion of the filing. DBV provided "virtually no detail" on the scope of the FDA's questions on manufacturing procedures and quality controls, and the company likewise is not yet prepared to benchmark how long it will take until refiling is possible, Raymond tells investors in a research note titled "We Didn't See That One Coming: DBV's BLA Withdrawal Clears the Way for AIMT." With Viaskin Peanut "sidelined for some time," the analyst believes Aimmune will benefit from less competitive concerns for AR101. Further, Raymond spoke to Aimmune management and learned that the company had extensive discussions on manufacturing with the FDA. Aimmune came away confident in the AR101 filing, says the analyst.
DCPH Deciphera
$22.42

1.49 (7.12%)

12/04/18
RHCO
12/04/18
DOWNGRADE
Target $75
RHCO
Hold
Tesaro downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Tesaro (TSRO) to Hold from Buy and raised his price target to $75 from $65 after its announcement of being acquired by Glaxo SmithKline (GSK). The analyst believes that the $75 per share offer price is "fair" and expects the deal, which he views as potentially positive for peers and for the biotech tape, to be completed in Q1 of 2019. Lawson anticipates that other companies with DNA damage response targeting drugs such as Sierra Oncology (SRRA), as well as immunoefficiency pipeline peers including MacroGenics (MGNX), Array Biopharma (ARRY), and Deciphera Pharmaceuticals (DCPH) could benefit from the announcement.
12/31/18
RILY
12/31/18
UPGRADE
Target $34
RILY
Buy
Deciphera resumed with a Buy from Neutral at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Deciphera Pharmaceuticals and upgraded the shares to Buy from Neutral. The analyst raised his price target for the shares to $34 from $27.
11/16/18
LEER
11/16/18
NO CHANGE
Target $20
LEER
Outperform
Deciphera price target lowered to $20 from $28 at Leerink
Leerink analyst Andrew Berens lowered his price target for Deciphera Pharmaceuticals (DCPH) to $20 from $28 and reiterates an Underperform rating on the name. The updated data for avapritinib from Blueprint Medicines (BPMC) in gastro-intestinal stromal tumors reaffirmed a leading position in PDGFRalpha and 4L GIST, and demonstrated early activity in 2L patients, Berens tells investors in a research note. He believes this challenges key tenets of Dicephera's DCC-2618 value proposition. The analyst also thinks the weakness in Blueprint shares yesterday was due in part to a misunderstanding of the early second-line data that were presented, in addition to the safety concerns. Berens keeps an Outperform rating on Blueprint.
11/15/18
PIPR
11/15/18
NO CHANGE
Target $50
PIPR
Overweight
Deciphera remains well positioned after Blueprint data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Deciphera Pharmaceuticals (DCPH) following the presentation of gastrointestinal tumors data from Blueprint Medicines' avapritinib at the Connective Tissue Oncology Society meeting. While avapritinib second-line data looks comparable to Deciphera's DCC-2618, this included patients dosed at higher levels than what is going forward commercially and into registration trials, Raymond tells investors in a research note. In later lines avapritinib's overall response rate was higher than DCC-2618 but other measures are almost indistinguishable, says the analyst. Raymond views the efficacy data as "relatively comparable" between the two agents but says Deciphera's DCC-2618 has a "far better safety profile." As such, he continues to see the company as well positioned in gastrointestinal tumors. Deciphera is up 11% to $22.94 in morning trading while Blueprint is down 6% to $52.70.
RIGL Rigel Pharmaceuticals
$2.35

0.05 (2.17%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/29/18
HCWC
10/29/18
NO CHANGE
Target $7.5
HCWC
Buy
Rigel inked Asian partnership well ahead of schedule, says H.C. Wainwright
Rigel Pharmaceuticals this morning announced that it entered into a Tavalisse partnership with Kissei Pharmaceuticals to develop and commercialize the drug in Japan, China, Taiwan, and the Republic of Korea, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The company had been projecting Asian and European partnerships by mid-2019, and the first has now been delivered well ahead of schedule, says the analyst. He believes Rigel is also likely to deliver on the Europe deal ahead of schedule as well. The analyst reiterates a Buy rating on Rigel Pharmaceuticals with a $7.50 price target.
10/29/18
PIPR
10/29/18
NO CHANGE
Target $8
PIPR
Overweight
Piper remains buyer of Rigel after Tavalisse deal for Asia
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Rigel Pharmaceuticals with an $8 price target following this morning's announcement that an agreement has been reached with Kissei Pharmaceutical to bring Tavalisse to market in Asia. The analyst expected a deal like this, but not until the first half of 2019. He's "encouraged "by Tavalisse's continued progress and remains a buyer of Rigel Pharmaceuticals shares.
11/06/18
PIPR
11/06/18
NO CHANGE
Target $8
PIPR
Overweight
Rigel Pharmaceuticals saw 'impressive' Tavalisse quarter, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Rigel Pharmaceuticals after its Q3 results, citing its revenue beat. The analyst states that the management commentary has indicated a "limited payer pushback, physician satisfaction and breadth of prescribing" for Tavalisse, which suggests that its launch is off to a good start. Raymond maintains a positive outlook for Rigel Pharmaceuticals on Tavalisse opportunity as the launch progresses.
CELG Celgene
$66.65

2.51 (3.91%)

12/21/18
BTIG
12/21/18
INITIATION
BTIG
Neutral
Celgene assumed with a Neutral at BTIG
BTIG analyst Thomas Shrader last night assumed coverage of Celgene with a Neutral rating. Revlimid will face full generic competition in 2026 and possibly sooner, Shrader tells investors in a research note. He adds that while Celgene has been building a pipeline, he believes only luspatercept and Otezla have a high chance of blockbuster potential.
12/20/18
BTIG
12/20/18
INITIATION
BTIG
Neutral
Celgene resumed with a Neutral rating at BTIG
01/03/19
PIPR
01/03/19
NO CHANGE
Target $23
PIPR
Overweight
Bristol acquisition of Celgene a positive for Fate, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes Bristol-Myers Squibb's (BMY) agreement to acquire Celgene (CELG) is in part driven by the long-term potential of cellular therapies to treat cancer. The analyst sees the deal announced this morning as a positive for Fate Therapeutics (FATE), which he notes is developing a pipeline of allogeneic and induced pluripotent stem cell natural killer and T-cell therapies. Fate is a potential acquisition target for its "rich cell therapy pipeline and platform," Tenthoff tells investors in a research note. Fate remains a top pick for Piper in 2019 and the analyst reiterates an Overweight rating on the shares with a $23 price target.
12/03/18
PIPR
12/03/18
NO CHANGE
PIPR
Overweight
Regeneron's REGN1979 'best in show' thus far at ASH, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond calls Regeneron Pharmaceuticals' (REGN) REGN1979 the "best in show" thus far at this year's American Society of Hematology meeting. The analyst says this weekend's updates were largely consistent with his expectations except for the "overwhelmingly impressive data" from REGN1979 in relapsed or refractory follicular lymphoma. This asset could serve as a "significant value driver" for Regeneron shares and the stock is likely to be up sharply today, Raymond tells investors in a research note. He adds that REGN1979 is currently not in his Regeneron model. Following the weekend's updates the analyst keeps Overweight ratings on BioMarin (BMRN) and Regeneron and a Neutral rating on Celgene (CELG).
BMY Bristol-Myers
$52.02

0.46 (0.89%)

12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/06/18
12/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Activision Blizzard (ATVI) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying the stock is down 45% from an all-time high in early October, and now trades at 16.5 times forward consensus earnings, compared to 25.5 times and 23.0 times on average over the prior one and three year periods. 2. Bristol-Myers (BMY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying the risk-reward on the stock at current price "seems attractive." 3. Hostess Brands (TWNK) upgraded to Overweight from Neutral at JPMorgan analyst Ken Goldman saying by this time next year, today's two major headwinds - lost business with Walmart (WMT) and the "EBITDA-hemorrhaging" Cloverhill acquisition - will be lapped and potentially become tailwinds. 4. Spirit Airlines (SAVE) upgraded to Outperform from Neutral at with analyst Jose Caiado De Sousa saying after a "massive" Q4 unit revenue guidance boost last week, the analyst sees further upside in the equity into H1 of 2019, with expected continued momentum in non-ticket revenue production amid a lower oil environment and a benign competitive backdrop. 5. Synopsys (SNPS) upgraded to Buy from Hold at Benchmark with analyst Gary Mobley citing slightly better than expected Q4 results and in-line FY19 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/18
JPMS
12/06/18
NO CHANGE
Target $70
JPMS
Overweight
JPMorgan still sees path to substantial Opdivo growth despite Bristol's setbacks
JPMorgan analyst Chris Schott said that investors are clearly concerned about Opdivo growth following several recent setbacks for Bristol-Myers, including mixed TMB data, pending RCC competition, and a failed SCLC study, but he still sees a path to substantial growth for the drug based on the numerous important readouts in both lung and non-lung indications coming in the next 12 months. Meanwhile, his analysis suggests Bristol-Myers' share price reflects little, if any, Opdivo growth from current levels. Given his view, and its convergence with what he believes to be the consensus view, on Opdivo, Schott sees the long term risk/reward for Bristol shares as highly attractive and keeps an Overweight rating on the stock with a $70 price target.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.